All News


Investors head for the central nervous system

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Why isn't Europe working?

European biotech is a hot topic among investors. They have supported as many start-ups as in the US but have seen far from equivalent returns. So what's going on? Science|Business talks to biotechnology consultant John Hodgson.

Can biotechnology embrace openness?

Open source software has broken the stranglehold of proprietary software vendors. Could the Biological Open Source initiative do the same in biotech?